Richard Lewis
Overview
Explore the profile of Richard Lewis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
1702
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berry J, Maragakis N, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA
. 2025 Mar;
PMID: 40067821
Importance: Bioenergetic failure has been proposed as a driver of amyotrophic lateral sclerosis (ALS). CNM-Au8 is a suspension of gold nanocrystals that catalyzes the conversion of nicotinamide adenine dinucleotide hydride...
2.
Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial
Andrews J, Paganoni S, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA Neurol
. 2025 Mar;
PMID: 40067754
Importance: Myeloperoxidase is one of the most abundant peroxidase enzymes in activated myeloid cells. Myeloperoxidase inhibitors may have a clinical benefit in amyotrophic lateral sclerosis (ALS) by slowing neurodegeneration via...
3.
Paganoni S, Fournier C, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2459058.
PMID: 39960672
Importance: The etiology of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, is unknown. However, neuroinflammation and complement activation may play a role in disease progression. Objective: To determine the...
4.
Lindborg S, Goyal N, Katz J, Burford M, Li J, Kaspi H, et al.
Muscle Nerve
. 2024 Apr;
69(6):719-729.
PMID: 38593477
Introduction/aims: Biomarkers have shown promise in amyotrophic lateral sclerosis (ALS) research, but the quest for reliable biomarkers remains active. This study evaluates the effect of debamestrocel on cerebrospinal fluid (CSF)...
5.
Vasilijic S, Atai N, Hyakusoku H, Worthington S, Ren Y, Sagers J, et al.
Sci Adv
. 2023 Nov;
9(45):eadf7295.
PMID: 37948527
Vestibular schwannoma (VS) is an intracranial tumor arising from neoplastic Schwann cells and typically presenting with hearing loss. The traditional belief that hearing deficit is caused by physical expansion of...
6.
Heger J, Mattlener J, Schneider J, Godel P, Sieg N, Ullrich F, et al.
Blood
. 2023 Nov;
143(6):522-534.
PMID: 37946299
State-of-the-art response assessment of central nervous system lymphoma (CNSL) by magnetic resonance imaging is challenging and an insufficient predictor of treatment outcomes. Accordingly, the development of novel risk stratification strategies...
7.
Pinczel A, Woods C, Catcheside P, Woodman R, Carney A, Chai-Coetzer C, et al.
Sleep
. 2023 Aug;
47(1).
PMID: 37607039
Study Objectives: The sleep apnea multi-level surgery (SAMS) randomized clinical trial showed surgery improved outcomes at 6 months compared to ongoing medical management in patients with moderate or severe obstructive...
8.
Lanini J, Santarossa G, Sirockin F, Lewis R, Fechner N, Misztela H, et al.
J Chem Inf Model
. 2023 Jul;
63(15):4497-4504.
PMID: 37487018
Machine-learning and deep-learning models have been extensively used in cheminformatics to predict molecular properties, to reduce the need for direct measurements, and to accelerate compound prioritization. However, different setups and...
9.
Owolabi M, Leonardi M, Bassetti C, Jaarsma J, Hawrot T, Makanjuola A, et al.
Nat Rev Neurol
. 2023 May;
19(6):371-383.
PMID: 37208496
The global burden of neurological disorders is substantial and increasing, especially in low-resource settings. The current increased global interest in brain health and its impact on population wellbeing and economic...
10.
Rehbein T, Wu T, Treidler S, Pareyson D, Lewis R, Yum S, et al.
Brain
. 2023 Mar;
146(9):3826-3835.
PMID: 36947133
Recessive SH3TC2 variants cause Charcot-Marie-Tooth disease type 4C (CMT4C). CMT4C is typically a sensorimotor demyelinating polyneuropathy, marked by early onset spinal deformities, but its clinical characteristics and severity are quite...